Inventory: A selection of Blod research on August 20, 2020.

1. The newly diagnosed standard first-line treatment for newly diagnosed patients with multiple myeloma (NDMM) after the treatment of the newly diagnosed transplantable multiple myeloma amine, boronitazome and dexamisong (RVd) is a newly diagnosed patient with multiple myeloma (NDMM).
recently evaluated the effectiveness of RVd combined with DDremu monoantigen (D) in NDMM patients who met ASCT conditions.
a total of 207 patients were randomly grouped 1:1 and received RVd-D induction (4 courses), ASCT, RVd-D consolidation (2 courses) and lynamine-D maintenance (26 courses).
in the main endpoint analysis, the strict full response rate (sCR) of patients treated with D-RVd was significantly better than that of patients treated with RV (42.4% vs 32.0%) at the end of ASCT post-consolidation therapy.
the degree of mitigation continued to increase as follow-up time increased (22.1 months in the middle time), and the sCR rate of D-RVd increased (62.6% vs 45.4%) compared to RVd.
D-RVd group and RVd group had 4 cases (3.8%) and 7 cases (6.8%) of patients with course progression, and the survival rate of no progression in 24 months was 95.8% (D-RVd) and 89.8% (RVd), respectively.
3/4 hematological adverse events in the D-RVd group were more common.
D-RVd group had more infections, but the 3/4 infection rate was similar, with no difference in the mesoth time between the two groups of neutral granulocytes and plateplate implants.
( 2) EMT regulatory factor SNAI1 promotes AML progress by interacting with LSD1 In recent years, the regulatory factor of endoskin-intercharged transformation (EMT) has become a new member of the field of leukemia biology.
the mechanism of EMT regulatory factors involved in leukemia is not yet fully clear.
recently, researchers found that the overexpeaturalization of SNAI1, a key regulatory factor of EMT, is a pathologically related event in human acute myeloid leukemia (AML), which can lead to impaired, self-renewal, and proliferation of immature myelin cell differentiation.
, the researchers also demonstrated in mice that Snai1's hetero-expression in hematocytes can lead to acute myeloid leukemia.
this effect is mediated by interaction with histogeneic demethylase KDM1A/LSD1.
14-3-3ζ-c-Src-integrative-beta-3 complex is essential for platelet activation In the process of thrombosis and hemostatic hemostatic, the adapter molecule binds to the inner end of the cell of beta-integratant, which promotes bidirectional signaling.
interfere with the integration-adapter interaction in space or time to inhibit thrombosis without affecting hemostage is an attractive strategy for developing safe anti-thrombosis agents.
researchers recently reported for the first time that a 14-3-3ζ-c-Src-integrin (integrated)-beta-3 complex is formed during plateplate activation.
14-3-3ζ-c-Src interactions are mediated by the SH2 domain on 14-3-3ζ (PE16) and C-Src, while 14-3-3ζ The interaction of -integrative-beta3 is mediated by the eskvfylkmkgdyrYL fragment (EL17) on 14-3-3ζ and the keatstf fragment (KF7) on the inner tail segment of the integrative-beta 3 cell.
EL17 mold inhibitors or FK7 peptides can interfere with the formation of 14-3-3ζ-c-Src-integrator-beta3 complex, selectively inhibit the extracellular-in-cell signaling of beta 3, and do not affect the interaction of the integrator-celloproteins, thereby inhibiting thrombosis without causing significant bleeding.
source: MedSci Originals !-- content presentation ends -- !-- to determine whether the login ends.